Exendin 4-Hapten Conjugate Capable of Binding with Endogenous Antibodies for Peptide Half-life Extension and Exerting Long-Acting Hypoglycemic Activity

Abstract

Hapten-specific endogenous antibodies are naturally occurring antibodies present in human blood. Herein, we investigated a new strategy in which small-molecule haptens were utilized as naturally occurring antibody binders for peptide half-life extension. The glucagon-like peptide 1 receptor agonist exendin 4 was site-specifically functionalized with the dinitrophenyl (DNP) hapten at the C-terminus via sortase A-mediated ligation. The resulting Ex4–DNP conjugates retained GLP-1 receptor activation potency in vitro and had a similar in vivo acute glucose-lowering effect comparable to that of native Ex4. Pharmacokinetic studies and hypoglycemic duration tests demonstrated that the Ex4–DNP conjugates displayed significantly elongated half-lives and improved long-acting antidiabetic activity in the presence of endogenous anti-DNP antibodies. In chronic treatment studies, once-daily administration of optimal conjugate 7 demonstrated more beneficial effects without prominent toxicity compared with Ex4. This strategy provides a new approach and represents an alternative to the well-established peptide-Fc fusion strategy to improve the peptide half-life and the therapeutic efficacy.

Dinitrophenol‐Hyaluronan Conjugates as Multivalent Antibody‐Recruiting Glycopolymers for Targeted Cancer Immunotherapy

“…The DNP derivatives (DNP-PEG m -NH 2 , m = 1, 3, 6, 10-12) with variable length of PEG linker were synthesized according to a procedure as we described previously. [27] Based on the binding profile of HA to its ligand CD44, 30 kDa of HA that is a commercially available and biocompatible material approved by FDA for medical application, containing ca. 79 disaccharides units, was chosen as the scaffold of MARGs in this case.…”

p75NTR antibody-conjugated microspheres: an approach to guided tissue regeneration by selective recruitment of endogenous periodontal ligament cells

“…Antibodies, with their capacity to identify and bind specific target antigens and their extended half-life in vivo ( Dai et al, 2021 ; Vantourout et al, 2021 ), emerge as a promising method for selective recruitment of cells ( Rosato et al, 2022 ). For example, T-cell engaging bispecific antibodies (BsAb) have been used by Niels et al to concurrently bind antigens on tumor cells and the CD3 subunit on T cells, thereby selectively recruiting T cells to eliminate tumor cells ( van de Donk and Zweegman, 2023 ).…”